Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Mirabegron confirmed safe and effective for overactive bladder syndrome

12 Jan 2020

Mirabegron may be used to effectively treat overactive bladder (OAB) syndrome without presenting new and pressing safety concerns, a recent study has found.

Pooling from 10 phase 2–4 double-blind, 12-week mirabegron trials, researchers reassessed the efficacy and safety of the drug against OAB syndrome. Safety was evaluated through the occurrence of treatment-emergent adverse events (TEAEs), while bladder diary data were used for the assessment of treatment efficacy.

Both the 25-mg and 50-mg doses of mirabegron significantly improved OAB symptoms relative to placebo. For instance, the mean number of 24-hour incontinence episodes dropped from 2.95±0.10 and 2.51±0.05 at baseline to 1.35±0.08 and 1.10±0.05 at end-of-treatment for either dose, respectively. The change observed with placebo, in comparison, was statistically smaller.

A similar effect was reported for the number of micturitions per 24 hours. Mirabegron 25 and 50 mg induced a decrease of 2.05±0.08 and 2.12±0.04 episodes from baseline to end-of-treatment, respectively, both significantly greater than the placebo treatment’s net change of –1.55±0.05. The same was true for urgency and nocturia episodes per 24 hours.

The mean voided volume was significantly increased after treatment with 25-mg (change, 15.94±1.37) and 50-mg (change, 23.17±0.84) mirabegron, likewise statistically outperforming placebo.

These improvements did not come with new safety signals. TEAEs included dry mouth, constipation, urinary tract infection, tachycardia and treatment-emergent hypertension. However, these occurred more commonly in patients treated with antimuscarinics vs mirabegron. Placebo treatments showed the lowest incidence of TEAEs.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 2 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 2 days ago
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.